Evaluation of blood flow of malignant tumor using O-15 water PET: the effect of blood flow on therapeutic response

Evaluation of blood flow of malignant tumor using O-15 water PET: the effect of blood flow on therapeutic response - Evaluation of blood flow of malignant tumor using O-15 water PET

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034193

Enrollment

Registered

2018-10-01

Start date

2019-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

O-15 water PET

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) In our respiratory department internal medicine patient who had lung cancer before chemotherapy with anticancer drug for the first time. However, patients with adjuvant chemotherapy and chemoradiotherapy are excluded. Treatment history of molecular targeted drugs other than chemotherapy with cell-mediated anticancer drugs, surgery, radiotherapy and the like is not limited. 2) Adult patients over the age of 20 3) Patients who have written written consent about their participation in this study at their own will

Exclusion criteria

Exclusion criteria: 1) Patients who are assumed to be difficult to implement this PET examination due to general condition etc. 2) Women who are pregnant 3) Other patients who are judged inappropriate by research researcher, etc.

Design outcomes

Primary

Measure	Time frame
Tumor blood flow in patients with lung cancer	—

Countries

Japan

Contacts

Public ContactTadashi Watabe

Osaka University Graduate School of Medicine Nuclear Medicine and Tracer Kinetics

watabe@tracer.med.osaka-u.ac.jp06-6879-3461

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026